Literature DB >> 2218553

A long-term study of interstitial lung disease in systemic lupus erythematosus.

L Weinrib1, O P Sharma, F P Quismorio.   

Abstract

The clinical course of chronic diffuse interstitial lung disease (ILD) was studied in 14 patients with SLE. The mean duration of follow-up was 7.3 years. All patients had dyspnea on exertion, pleuritic chest pain, chronic cough, and basilar rales. Chest roentgenogram showed diffuse or basilar infiltrates, pleural disease, and elevation of both diaphragms. Systemic corticosteroids were given early in the course of the illness for lung involvement and multisystem disease. Diffusing capacity for carbon monoxide (DLCO) and inspiratory vital capacity (IVC) improved or remained unchanged in the majority of patients. Respiratory complaints improved in all patients; however, two patients died of pulmonary fibrosis and another died of bacterial pneumonia. Alveolar septal deposits of immunoglobulins and complement were found. This study showed that while variability existed among individual subjects, the clinical progression of ILD was slow and tended to improve or stabilize with time.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2218553     DOI: 10.1016/0049-0172(90)90094-v

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  15 in total

Review 1.  Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors:  M P Keane; J P Lynch
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

2.  Systemic lupus erythematosus arising in a patient with chronic silicosis.

Authors:  K Ozoran; H Uçan; H Tutkak; N Caner; M Yücel
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

3.  Comparative analysis of mediastinal fat-associated lymphoid cluster development and lung cellular infiltration in murine autoimmune disease models and the corresponding normal control strains.

Authors:  Yaser Hosny Ali Elewa; Osamu Ichii; Yasuhiro Kon
Journal:  Immunology       Date:  2015-11-16       Impact factor: 7.397

4.  Serologic phenotypes distinguish systemic lupus erythematosus patients developing interstitial lung disease and/or myositis.

Authors:  Thaisa Cotton; Marvin J Fritzler; May Y Choi; Boyang Zheng; Omid Zahedi Niaki; Christian A Pineau; Luck Lukusa; Sasha Bernatsky
Journal:  Lupus       Date:  2022-08-26       Impact factor: 2.858

5.  An 8-year follow-up study of pulmonary function in patients with rheumatoid arthritis.

Authors:  M Linstow; C S Ulrik; N J Kriegbaum; V Backer; P Oxholm
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

6.  Prolidase deficiency associated with systemic lupus erythematosus (SLE): single site experience and literature review.

Authors:  Yonatan Butbul Aviel; Hana Mandel; Emily Avitan Hersh; Reuven Bergman; Orly Eshach Adiv; Anthony Luder; Riva Brik
Journal:  Pediatr Rheumatol Online J       Date:  2012-06-22       Impact factor: 3.054

Review 7.  Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.

Authors:  So-My Koo; Soo-Taek Uh
Journal:  Korean J Intern Med       Date:  2017-06-30       Impact factor: 2.884

Review 8.  Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).

Authors:  Adelle S Jee; Stephen Adelstein; Jane Bleasel; Gregory J Keir; MaiAnh Nguyen; Joanne Sahhar; Peter Youssef; Tamera J Corte
Journal:  J Clin Med       Date:  2017-05-04       Impact factor: 4.241

Review 9.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Authors:  Caterina Vacchi; Marco Sebastiani; Giulia Cassone; Stefania Cerri; Giovanni Della Casa; Carlo Salvarani; Andreina Manfredi
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

Review 10.  Pathological interpretation of connective tissue disease-associated lung diseases.

Authors:  Kun Young Kwon
Journal:  Yeungnam Univ J Med       Date:  2019-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.